Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study

Pierre Mordant,Solenn Brosseau,Bernard Milleron,Nicola Santelmo,Séverine Fraboulet-Moreau,Benjamin Besse,Alexandra Langlais,Dominique Gossot,Pascal-Alexandre Thomas,Jean-Louis Pujol,Charles Ricordel,Jeannick Madelaine,Régine Lamy,Clarisse Audigier-Valette,Pascale Missy,Hélène Blons,Fabrice Barlesi,Virginie Westeel

Clinical Lung Cancer（2023）

引用 4|浏览11

暂无评分

摘要

•In France, epidermal growth factor receptor mutations are present in 12.9% of the resected stage I-II.•Epidermal growth factor receptor mutations have no impact on disease-free survival and overall survival.•Patients with resected stage I-II non-small cell lung cancer have a 5-year Disease-Free Survival of 65% and a 5-year overall survival of 75%.

查看译文

关键词

NSCLC,Surgery, Molecular profile, Prognosis,Stage I-II disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要